Fundamental and Advanced Therapies, Vaccine Development against SARS-CoV-2
Open Access
Abstract
Coronavirus disease (COVID-19) caused by the SARS-CoV-2 virus has been affecting the world since the end of 2019. The severity of the disease can range from an asymptomatic or mild course to acute respiratory distress syndrome (ARDS) with respiratory failure, which may lead to death. Since the outbreak of the pandemic, scientists around the world have been studying the genome and molecular mechanisms of SARS-CoV-2 infection to develop effective therapies and prevention. In this review, we summarize the progressive development of various treatments and vaccines as they have emerged, a year after the outbreak of the pandemic. Initially for COVID-19, patients were recommended drugs with presumed antiviral, anti-inflammatory, and antimicrobial effects that were previously used to treat other diseases. Thereafter, therapeutic interventions were supplemented with promising approaches based on antibodies, peptides, and stem cells. However, licensed COVID-19 vaccines remain the most effective weapon in combating the pandemic. While there is an enormous effort to enhance the vaccination rate to increase the entire population immunity, the production and delivery of vaccines is becoming limited in several countries. In this regard, there are new challenges needing to be addressed by combining non-pharmacological intervention with effective therapies until vaccination is accessible to all.Keywords
Funding Information
- Agentúra na Podporu Výskumu a Vývoja (PP-COVID-20-0044, APVV-18-0259, APVV-19-0193)
This publication has 150 references indexed in Scilit:
- Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virusBiochemical Journal, 2012
- Let-7 microRNA–mediated regulation of IL-13 and allergic airway inflammationJournal of Allergy and Clinical Immunology, 2011
- Virucidal activity of a scorpion venom peptide variant mucroporin-M1 against measles, SARS-CoV and influenza H5N1 virusesPeptides, 2011
- Antibacterial Effect of Human Mesenchymal Stem Cells Is Mediated in Part from Secretion of the Antimicrobial Peptide LL-37Stem Cells, 2010
- Increased Expression of Angiotensin Converting Enzyme 2 in Conjunction with Reduction of Neointima by Angiotensin II Type 1 Receptor BlockadeHypertension Research, 2008
- Severe Acute Respiratory Syndrome Coronavirus ORF6 Antagonizes STAT1 Function by Sequestering Nuclear Import Factors on the Rough Endoplasmic Reticulum/Golgi MembraneJournal of Virology, 2007
- Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal modelVaccine, 2007
- Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2Circulation, 2005
- IMPROVED OUTCOME OF ORTHOTOPIC LIVER TRANSPLANTATION FOR CHRONIC HEPATITIS B CIRRHOSIS WITH AGGRESSIVE PASSIVE IMMUNIZATIONTransplantation, 1996
- Use of Convalescent Measles Serum to Control Measles in a Preparatory SchoolAmerican Journal of Public Health and the Nations Health, 1935